BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)
(“BriaCell” or the “Company”), a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care, is pleased to announce the formation of its medical advisory
board and the appointment of three distinguished breast cancer key
opinion leaders (KOLs) Massimo Cristofanilli, MD, FACP, Sara A.
Hurvitz, MD, FACP, and Adam M. Brufsky, MD, PhD, as well as the
addition of Charles Sidman, PhD, MBA, to its scientific advisory
board.
“We are extremely privileged to have these
leading experts on state-of-the art breast cancer clinical research
and drug development as our advisors,” stated Dr. William V.
Williams, BriaCell’s President and CEO. “Their expert insights and
dedication to unparalleled patient care will be invaluable to us in
our pivotal Phase 3 registration study.”
“At BriaCell, we are committed to developing
novel immunotherapies to transform cancer care,” stated Dr. Del
Priore, BriaCell’s Chief Medical Officer. “Having world-class
scientists and authoritative breast cancer experts on our side will
enable us to better analyze the science behind the positive
clinical and survival outcomes and help direct our approach as we
seek to achieve more desirable outcomes for advanced breast cancer
patients in need.”
BriaCell’s medical advisory board consist of the
following members:
Massimo Cristofanilli, MD,
FACP: Dr. Cristofanilli currently serves as Chief, Breast
Medical Oncology; Associate Director, Precision Medicine Oncology
at the Sandra and Edward Meyer Cancer Center; Scientific Director,
the Englander, Institute of Precision Medicine. He obtained his
medical degree from the University “La Sapienza” in Rome with
Honors where he completed his fellowship in medical oncology.
Subsequently, he completed a medical oncology fellowship at The
University of Texas MD Anderson Cancer Center, where he also served
as Faculty in the Department of Breast Medical Oncology for over a
decade. Dr. Cristofanilli’s extensive academic experience includes
roles as Chairman of Medical Oncology and Associate Director of
Clinical Research at the Fox Chase Cancer Center, Associate
Director of Translational Research at Thomas Jefferson University,
Professor of Medicine at the Robert H. Lurie Comprehensive Cancer
Center at Northwestern University, Chicago and Director of Robert
Lurie Cancer Center OncoSET Precision Medicine Program His research
on biomarkers of endocrine resistance in breast cancer, liquid
biopsies, novel drug development, circulating tumor cells (CTCs)
and ctDNA have led to improved care for breast cancer patients. He
is recognized for his contribution to the field of drug development
in metastatic and locally advanced breast cancer and Inflammatory
Breast Cancer (IBC), the detection and monitoring of micro
metastatic disease in breast cancer. Moreover, he is Founder and
President of the IBC International Consortium and has co-authored
more than 400 peer-reviewed manuscripts.
Sara Hurvitz, MD, FACP: Dr.
Hurvitz currently serves as Professor of Medicine, Senior Vice
President of the clinical research division at Fred Hutchinson
Cancer Center, and Head of the division of hematology and oncology
at the University of Washington Department of Medicine in Seattle.
Previously, she directed the breast oncology program at the
University of California, Los Angeles (UCLA) and also served as
Professor of medicine at UCLA’s David Geffen School of Medicine;
Co-Director of the Santa Monica-UCLA outpatient oncology practice;
Medical Director of the clinical research unit of the UCLA Jonsson
Comprehensive Cancer Center and Director of the breast cancer
clinical trials program at UCLA. She has won numerous awards
including the 2023 ESMO Breast Award and the Marni Levine Memorial
Breast Cancer Research Award, and has been named to several
prestigious lists including Super Doctors® Southern California, Top
Doctors, Los Angeles Magazine, America’s Most Honored Doctors – Top
1%, Castle Connolly Exceptional Women in Medicine, Castle Connolly
Top Doctors, California, Southern California Super Doctors, UCLA
Health “100 in 100” Trailblazing Women Honoree, Southern California
Top Doctors, Best Doctors in America, and Top Women Southern
California Super Doctors. Dr. Hurvitz obtained her medical degree
from Keck School of Medicine of University of Southern California
in 1999 and completed both her internal medicine residency and
hematology/oncology fellowship at UCLA. She is board certified in
internal medicine and medical oncology.
Adam M. Brufsky, MD, PhD: Dr.
Brufsky is Professor of Medicine at the University of Pittsburgh
School of Medicine. He serves as Co-Director, Comprehensive Breast
Cancer Center and Medical Director, Women’s Cancer Center at the
UPMC Magee Women’s Hospital, Pittsburgh, PA. Dr. Brufsky received
an AB in Chemistry (Cum Laude) from Dartmouth College in Hanover,
New Hampshire. He earned his MD and his PhD in Developmental
Biology at the University of Connecticut School of Medicine in
Farmington, CT. He was an Intern and Resident in Internal Medicine
at Brigham and Women’s Hospital, Harvard Medical School, Boston,
MA. He then completed a Fellowship in Medical Oncology and Bone
Marrow Transplantation and the Dana-Farber Cancer Institute,
Harvard Medical School, Boston, MA, where his appointments included
Associate Physician and Instructor in Medicine at Dana Farber
Cancer Institute and Harvard Medical School in Boston, MA. Dr.
Brufsky is board certified in Internal Medicine and Medical
Oncology by the American Board of Internal Medicine. He is an
active member of the American Society of Clinical Oncology and the
American Association for Cancer Research. He has authored or
co-authored more than 300 abstracts and research articles in
leading journals, including the New England Journal of Medicine,
Journal of Clinical Investigation, Journal of Clinical Oncology,
and Lancet Oncology. Dr. Brufsky is a Principal Investigator on a
number of research grants funded by the National Institutes of
Health, Susan G. Komen Foundation, and US Army Breast Cancer
Research Program.
Separately, BriaCell added Dr. Sidman to its
scientific advisory board.
Charles Sidman, PhD, MBA: Dr.
Sidman currently serves as Founder and Managing Partner, ECS
Capital Partners, LLC. Dr. Sidman’s academic career includes
experience as Research Fellow in Pathology at Harvard Medical
School, Member of the Basel Institute for Immunology in Basel,
Staff Scientist at The Jackson Laboratory in Bar Harbor, and
Professor of Molecular Genetics, Biochemistry, Microbiology, and
Management at the University of Cincinnati. His first professional
effort was in computer science, in which he pioneered what became
known decades later as Artificial Intelligence. In biomedicine, he
worked with eminent colleagues in genetics and immunology to help
enable current exciting applications in these fields. Dr. Sidman
has invested in multiple start- up companies through over 100
rounds, acted as Chairman of 4, and board member of another 5. He
is Founding Chairman of Maine Angels, Founding Member of the Angel
Capital Association, former Board Member of the World Business
Angel Forum, former Chair of the Strategy and Education Committees
of the National Association of Seed and Venture Funds, Founding
Member and President of the Crowdfunding Professional Association,
and recipient of special recognition from the European Business
Angel Network. Dr. Sidman earned his AB degree in Biochemical
Sciences, AM degree in Biochemistry, and PhD in Immunology, all
from Harvard, and his MBA from the University of Cincinnati. He has
lectured or consulted at some of the world’s leading universities,
research centers and companies, and has authored over 100
publications in immunology, patent reform, crowdfunding, and
government roles in tech transfer and early-stage investing.
About BriaCell Therapeutics
Corp.
BriaCell is a clinical-stage biotechnology
company that develops novel immunotherapies to transform cancer
care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements, including in relation to the ability of the medical
advisory board to assist the Company with its registration studies,
developing novel immunotherapies and achieving desirable outcomes
for advanced breast cancer patients, are based on BriaCell’s
current expectations and are subject to inherent uncertainties,
risks, and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate. These and other
risks and uncertainties are described more fully under the heading
“Risks and Uncertainties” in the Company's most recent Management’s
Discussion and Analysis, under the heading "Risk Factors" in the
Company's most recent Annual Information Form, and under “Risks and
Uncertainties” in the Company's other filings with the Canadian
securities regulatory authorities and the U.S. Securities and
Exchange Commission, all of which are available under the Company's
profiles on SEDAR at www.sedar.com and on
EDGAR at www.sec.gov. Forward-looking statements
contained in this announcement are made as of this date, and
BriaCell Therapeutics Corp. undertakes no duty to update such
information except as required under applicable law.
Neither the Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTXW)
過去 株価チャート
から 8 2024 まで 9 2024
BriaCell Therapeutics (NASDAQ:BCTXW)
過去 株価チャート
から 9 2023 まで 9 2024